REC Rydex Inverse 2X S&P Select Se

• Consolidated revenue € 260.4 million, +6.5%.
• EBITDA(1) € 71.4 million, +16.4%
• Operating income € 62.2 million, +18.1%.
• Net income € 42.8 million, +13.2%.
• Net financial position(2):  net debt of € 229.1 million.
• Exclusive license agreement with Apricus Biosciences for Vitaros®.
• Full year 2014 targets: sales slightly below € 1,000 million, operating income above € 220 million and net income above € 150 million.

The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first quarter 2014 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website: http://www.recordati.it/investors/reports/2014.aspx?sc_lang=en and can also be viewed on the website of Borsa Italiana S.p.A.

Financial highlights

• Consolidated revenue in the first quarter 2014 is € 260.4 million, up by 6.5% compared to the same period of the preceding year. International sales grow by 7.0%.  
• EBITDA(1), at 27.4% of sales, is € 71.4 million, an increase of 16.4% over the same period of the preceding year.  
• Operating income, at 23.9% of sales, is € 62.2 million, an increase of 18.1%.  
• Net income, at 16.4% of sales, is € 42.8 million, an increase of 13.2% over the first quarter of 2013.  
• Net financial position(2) at 31 March 2014 records a net debt of € 229.1 million. Shareholders' equity increases to € 742.2 million.

              (1) Earnings before interest, taxes, depreciation and amortization. (2) Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).

Business development news

In February an exclusive license agreement was entered into with Apricus Biosciences Inc., a pharmaceutical company based in San Diego, U.S.A., for the marketing and sales of Vitaros® (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain W. European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia, Ukraine and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.

Vitaros® is approved for the treatment of erectile dysfunction by a number of European health authorities and by Health Canada.  Vitaros® is a topically-applied cream formulation of alprostadil, a vasodilator, which directly increases blood flow to the penis, causing an erection. Alprostadil is an alternative to the PDE-5 inhibitors for difficult to treat patients, and Vitaros® offers a patient-friendly form versus other alprostadil dosage forms.

Management Comments

"The first quarter results are particularly positive; the consolidation of the new companies acquired at the end of 2013 and the performance of our product portfolio have allowed us to further improve our profitability", declared Giovanni Recordati, Chairman and CEO. "For the full year 2014 we confirm our expectations to achieve operating income of more than € 220 million and net income of more than € 150 million thanks to margin improvement. Revenues, as of today, are expected to be slightly below € 1,000 million due to a significant negative currency effect."

Conference call

Recordati will be hosting a conference call today 6 May 2014 at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The dial-in numbers are:

Italy                             +39 02 8058811, toll free 800 213 858 UK                                +44 1 212818003, toll free 800 0156384 USA                             +1 718 7058794, toll free 855 2656959 France                        +33 170918703 Germany                   +49 65 255114451

Callers are invited to dial-in 10 minutes before conference time.  If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371.  A recording of the conference call will be placed on the website www.recordati.com.

A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.

Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America.  An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases.  Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website:  www.recordati.com

Investor Relations                                                       Media Relations                                    Marianne Tatschke                                                      Ketchum                                 (39)0248787393                                                          Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com e-mail: inver@recordati.it                                          Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com                                                                                 

S tatements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI GROUP Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) (thousands of €)

Earnings per share (EPS) are based on average shares outstanding during each year, 202.722.546  in 2014 and 200.796.533 in 2013, net of average treasury stock which amounted to 6.402.610 shares in 2014 and to 8.328.623 shares in 2013. Diluted earnings per share is calculated taking into account stock options granted to employees.

RECORDATI GROUP Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) (thousands of €)

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE 1°Q http://hugin.info/143644/R/1783016/610489.pdf

HUG#1783016

Rydex Inverse 2X S&P Select Se (NYSE:REC)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Rydex Inverse 2X S&P Select Se (NYSE:REC)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025